Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
deals
life sciences
national blog main
national top stories
4
×
boston top stories
clinical trials
new york blog main
new york top stories
san francisco blog main
san francisco top stories
alnylam pharmaceuticals
fda
indiana blog main
indiana top stories
ipo
novartis
rna interference
san diego blog main
san diego top stories
sanofi
startups
wisconsin blog main
wisconsin top stories
abbvie
acetylon pharmaceuticals
akouos
alexion pharmaceuticals
alirocumab
allergan
alnylam pharmaceutials
amag pharmaceuticals
ambys medicines
amgen
amunix
anirvan ghosh
arrowhead pharmaceuticals
astrazeneca
biogen
What
deal
4
×
medicines
4
×
new
abandoning
acquire
acquisitions
ago
agreed
aiming
ambys
announced
baggage
big
billion
bio
biotech
brings
cash
ceo
cholesterol
collabs
companies
company
compound
control
covid
cuts
daniel
deadly
debuted
development
dicerna
diseases
drug
fda
formed
free
future
gets
gilead
Language
unset
Current search:
medicines
×
" national top stories "
×
deal
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?